As 2021 draws to a close we are very pleased to be recognized for excellent patient care based on authentic and verified patient reviews. Grateful for a great team! You can read the reviews here: https://www.doctify.com/en-ae/practice/dr-humeira-badsha-medical-center
View the full list of Patient Voice Award Shortlist: https://doctors.doctify.co.uk/uae-awards-winners/
We’d like to extend a warm welcome to Humeira Badsha Medical Centre for all specialities. The clinic in our new location at the Marina is fully open and functioning with thorough sanitization and social distancing procedures as per the Dubai Health Authority. We can’t wait to see you again!⠀
For appointments and inquiries, kindly call our clinic at 043856009, WhatsApp on 0563643215 email us on [email protected], or this link
Due to the COVID-19 pandemic, we are limiting in-person appointments until further notice. We are available for online and teleconsultations, and we are still able to do your lab tests.
For appointments and enquiries:
📧Email us at [email protected]
☎️Mobile & Whatsapp 056 364 3215
☎️Mobile: 050 534 3182
In light of the recent events, we’re doing whatever we can to keep you and our staff safe.
Part of our social responsibility is to practice distancing and stay at home when we can. In order for all of us to achieve this, we’re offering a telehealth service. This means we will be performing online consultations for our patients.
As per the directive of Dubai Health Authority we will be conducting all our clinical care via telemedicine platforms till further notice. This will eliminate the need for clinic visits. We are working on the best system which ensures your confidentiality and is compliant with the rules of Dubai authorities.
In the meantime you can contact us by phone on 04 385 6009 or Mobile & Whatsapp 056 364 3215. You can also email
[email protected] or [email protected].
Take care of yourselves and your families.
💬 As part of our commitment to providing the utmost in specialty patient care, we will be moving to new premises in March 2020. Dr. Humeira Badsha Medical Center can then be found as below 👇
Our New Address: 27th floor, Al Habtoor Business Tower, Dubai Marina, Dubai
📍 Google Map Location: https://buff.ly/3c6hh4I
☎️ Phone: 04 385 6009
📱 Mobile & Whatsapp: 056 364 3215
⚠️ Our phone and mobile numbers will remain the same. We will be closed on March 1st & 2nd, opening in our new location for appointments from March 3rd 2020. Our entrance can be found facing the Al Habtoor Hotel, and valet parking is available. We’re looking forward to showing you around our new home, so come and see it for yourself!
We wish all our valued patients a happy and blessed Eid El Fitr. On this occasion, the clinic will be closed from Tuesday June 4 till Friday June 7. Clinic operations will resume on Saturday, 8 June.
Happy Eid! 🌹
Exciting News: Introducing Dr. William Hodge
We are extending the warmest of welcomes to Dr. William Hodge, who we’re thrilled to announce is joining the Dr. Humeira Badsha Medical Center Family. We already know he’ll make a great addition, and we’re sure our patients will think so too!
Coming to us via Harvard; where he both worked and studied, Dr. Hodge has had an extremely compelling career to date. Traveling throughout the U.S and the Middle East, Dr. Hodge’s contributions to Orthopedics cannot be understated.
Published in a plethora of journals, with patents in several techniques and devices, he has been on the cutting edge of Musculoskeletal issues for over 40 years. Dr. Hodge is also a prestigious award winner – the height of which came when he was awarded the Ellis Island Medal of Honor in International Medicine in 2009. Prior to his nomination, this award was given to Presidents and Nobel Prize recipients.
We’re sure he will continue to do great things at Dr. Humeira Badsha Medical Center and invite you to make an appointment. Speak to an Orthopaedic Surgeon of unparalleled expertise, right here in the heart of Dubai.
View Dr. William Hodge profile: https://www.drbadshamedical.com/doctor/william-hodge/
Contact us for further information-
Dr. Humeira Badsha Medical Center
2nd Floor, Emirates Hospital, Jumeirah Road, Dubai, U.A.E.
Telephone: +9714 385 6009
Mobile: +97156 364 3215
Email: appointment@drbadsha
Emirates Hospital ties up with rheumatology specialist centre Centre has treated over 13,000 patients since its establishment in 2012 Dubai: The Humeira Badsha Medical Centre (HBMC), a leading specialist facility in musculoskeletal diseases, announced its collaborating with Emirates Hospital as it officially opened its new facility in Dubai. Having treated over 13,000 patients since its […]
From 2nd April 2018, Dr. Humeira Badsha Medical Center (HBMC) is moving its clinic to the Emirates Hospital in Jumeirah, Dubai. Providing the same level of excellent care as usual in a brand new location, we’re looking forward to seeing you there.
Our new address is: 2nd Floor, Emirates Hospital, Jumeirah Road, Dubai, UAE.
Contact us with any inquiries on +971 56 3643215 or email [email protected]
Regenerative adjunctive treatment is the next logical step in the progression of surgical intervention. Biologically augmented or regenerative techniques are at the very forefront of modern treatment and have the potential to transform the practice of medicine and surgery significantly in a very short period. Less than 20 years ago, one of the first applications of platelet-rich growth factors was successfully used to help augment dental implantation.
From this starting point progressive advancements have been made, but much remains to be learned. Although the basic science remains in its infancy, especially in the areas of signaling, regulation, and mechanism, regenerative knowledge has expanded significantly in volume and across disciplines. The purpose of this review is to provide a road map of the significant developments in preclinical and clinical results involving biological solutions to improve rotator cuff, ligament, meniscus, and articular cartilage surgical repair.
A research paper on ‘Regenerative Treatments to Enhance Orthopedic Surgical Outcome’, Click to view the PDF
Background/Purpose
Prior to the establishment of RA standards set by the ACR, a widespread discrepancy was formed between practices, which were treating patients with RA with di!erent levels of care. Thus, in order to regulate quality, the ACR implemented the following quality indicators worldwide: tuberculosis screening prior to biological disease modifying drugs (DMARDs), periodic assessment of disease activity, functional status assessment, assessment and classification of disease prognosis, glucocorticoid management, treatment with DMARDs, and follow up treatment with DMARDs.
The aim of our study was to audit our management of RA patients, and assess whether the before mentioned quality indicators were being implemented in our practice and whether this was reflected in better RA disease control.
Click to view the full article in PDF
Abstract
To better understand the factors that affect low disease activity (DAS28 ≤ 3.2, LDA) in rheumatoid arthritis (RA) and barriers within the UAE, demographic/ treatment data and DAS28 scores were collected through chart reviews of 182 consecutive RA patients seen at a private clinic in Dubai over a 2-month period. Patients were separated into a LDA group and a group comprised of moderate (3.2 < DAS28 < 5.1) or high disease activity (DAS28 ≥ 5.1) (MHDA). We then examined variables that may be associated with LDA and re-examined the MHDA group for barriers. While 97 (53 %) of the 182 patients had achieved the treatment target of DAS28 ≤ 3.2, 85 (47 %) had MHDA. A significantly larger portion of LDA patients had been previously treated with sulfasalazine (36 in LDA vs. 14 in MHDA, P = 0.002) or was presently on biological treatments (24 vs. 9, P = 0.013). For the 85 MHDA patients, 40 (22 % of 182) exhibited resistant disease with 25 (13.7 % of 182) failing their current first tier disease-modifying anti-rheumatic drug (DMARD) treatment or combinations and 15 (8.2 % of 182) failing current anti-TNF or biologic treatment. Reasons listed were primarily socioeconomic with 40 % of the resistant disease group unable to afford biologicals and 52 % of the patientdriven preference group discontinuing DMARDs against professional advice. Going forward, emphasis on the agreement between patient and rheumatologist on treatment, specifically regarding how DMARDs help relieve symptoms and their proper use, could help reduce the percentage of MHDA patients in the UAE.
Keywords Rheumatoid arthritis · Disease activity score · Disease control · Treat to target
Click to view the full article in PDF
Bone Health – Five things Everyone needs to know on how to maintain strong bones
Click to view the full article in PDF
There can be five types of lupus:
Systemic lupus erythematosus (SLE) is the most common form and one which is referred to as “lupus“. This can affect many parts of the body In mild or serious tones. Though it’s seen mainly in women of child-bearing age, it can affect any time, in childhood or old age.
Discoid lupus erythematosus is a chronic skin disorder. Angry red rashes can appear anywhere on the body, including the face and scalp, lasting from a few days to years. with recurrence. They can become thick and scaly and cause scarring. A small percentage of people with discoid lupus have or subsequently develop SLE.
Subacute cutaneous. lupus erythematosus are skin lesions that appear on parts of the body exposed to sun. They are known to leave scars.
Drug-induced lupus is a form of lupus caused by medication. Some antlseizure and high blood pressure medication. and antibiotics. antifungals. thyroid medication. and oral contraceptive pills are known to have indu”ced lupus. Symptoms are similar to SLE’s – arthritis. rash, fever. and chest pain – and go away completely when the drug is stopped.
Click to view the full Types of Lupus article in PDF
Our research will be presented at American college of Rheumatology meeting in san Francisco this November 15.
Following the american college of rheumatology quality guidelines can enhance the safety of rheumatoid arthritis patients treated with disease modifying drugs. View the full research in PDF
ISO 10002
Copyright © 2023. All Rights Reserved.
